Drs. Neil Iyengar, Manali Bhave & Reshma Mahtani - Navigating AKT Inhibition Efficacy & Tolerability episode artwork

EPISODE · May 8, 2026 · 21 MIN

Drs. Neil Iyengar, Manali Bhave & Reshma Mahtani - Navigating AKT Inhibition Efficacy & Tolerability

from Community Health Media · host Community Health Media

How are clinicians optimizing the use of AKT inhibitors in HR-positive metastatic breast cancer?In this CHM Conversations episode, Drs. Neil Iyengar, Manali Bhave, and Reshma Mahtani explore the shifting second-line landscape for HR+/HER2- metastatic breast cancer. The discussion centers on the clinical integration of capivasertib and the necessity of biomarker testing—specifically PIK3CA, AKT, PTEN, and ESR1—following progression on CDK4/6 inhibitors.The panel emphasizes a proactive approach to toxicity, detailing how multidisciplinary care and early metabolic optimization can mitigate class-specific side effects like hyperglycemia, rash, and diarrhea. By focusing on patient education and glycemic control from the start of the treatment journey, clinicians can effectively balance the potent efficacy of PI3K/AKT/PTEN pathway inhibition with long-term tolerability.A valuable discussion for oncology clinicians navigating biomarker-driven care and targeted therapy management in metastatic breast cancer.🎧 Watch more expert-led oncology conversations from CHM Conversations.#BreastCancer #MetastaticBreastCancer #HRPositive #HER2Negative #Oncology #PIK3CA #AKT #PTEN #Capivasertib #Truqap #PrecisionOncology #TargetedTherapy #EndocrineTherapy #MedicalOncology #BreastOncology #CommunityHealthMedia–Thanks for watching!Our podcasts are also available on: • Spotify - https://spotf.fi/chm-podcast • Amazon Music - https://amazn.so/chm-podcast • Apple Podcast - https://podcasts.apple.com/us/podcast/community-health-media/id1837428248 • Castbox - https://castbox.fm/vh/6735434 • Goodpods - https://goodpods.com/profile/chm-111066 • iHeartRadio - https://iheart.com/podcast/291542082 • Pocket Casts - https://pca.st/3ncdh11o–Community Health Media (CHM) is your full service healthcare communications partner, combining our production expertise with targeted multi-channel campaigns. We connect companies and healthcare brands with key opinion leaders, patients, and consumers through compelling content and live experiences.We’re an integrated marketing company that produces world-class content and curated peer to peer live experiences.We specialize in: • Peer to peer interviews, panels & round-tables • Curated live events & conferences • Professional in-depth content & research updates • Interactive learning modules & webinars • Live & on-demand webcasts & podcastsLearn more about us here - https://communityhealth.media

Episode metadata supplied by the publisher feed · Published May 8, 2026

Embed this episode

Ready to play

Drs. Neil Iyengar, Manali Bhave & Reshma Mahtani - Navigating AKT Inhibition Efficacy & Tolerability

0:00 21:45

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Community Health Media?

This episode is 21 minutes long.

When was this Community Health Media episode published?

This episode was published on May 8, 2026.

Can I download this Community Health Media episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!